A decisive turning point to change scale
At a key moment in its development, THX Pharmaformerly Theranexus, is beginning a major transformation: moving from the status of a biotech to that of a pharmaceutical company.
This change in dimension occurs in a strategic context. Winner of the France 2030 program, the Lyon-based company is part of an international growth dynamic.
In this context, this innovative company calls on our communications teams based in the United States to support it in its communication challenges and structuring of its image.
A first mission carried out in record time
The collaboration began with a request with important challenges: redesign of the logo, design of a deck and creation of a landing page announcing the change of name.
Everything had to be completed in record time, to meet tight deadlines linked to a public announcement.
« The team was able to respond within extremely short deadlines, while maintaining a high level of quality. This allowed us to approach this key stage with solid and consistent support »
This rebranding work had a clear objective: to maximize the chances of success of the fundraising by aligning the company’s image with its new positioning.
A visual identity aligned with ambitions
Beyond this first phase, in-depth work was carried out on the graphic charter and communication supports.
The challenge was to visually translate the ambitions of THX Pharma, by integrating the codes of a niche sector, mainly dominated by the North American market.
« We were particularly struck by the teams’ ability to quickly understand our model and to visually translate what we wanted to express in terms of image and positioning. »
This support allowed the company to structure its communication and gain clarity in a strategic period.
A lever to structure growth
This work helped to strengthen the company’s credibility with its partners and investors.
« Between the initial version of our presentation and the reworked one, there is a real increase in quality. We have gained clarity, credibility and impact »
THX Pharma thus successfully raised funds of 8 million euros, followed by the signing of a strategic agreement with the pharmaceutical laboratory Biocodex.
A long-term collaboration
Very satisfied with this support, the THX Pharma teams wanted to extend the collaboration with the American communications team.
« This first experience made us want to go further. The first results, particularly on the site, are already very encouraging. »Â
With a clear international roadmap and communication tools now aligned with its ambitions, THX Pharma is giving itself the means to succeed in its change of scale.
